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ABSTRACT.
Alzheimer’s disease is a neurodegenerative disease and the most common cause
of senile dementia. It impairs the quality of life of a person and their family,
posing a serious economic and social threat in developed countries. The fact that
the diagnosis can only be deﬁnitively made post-mortem, or when the disease is
fairly advanced, presents a serious problem if novel therapeutic interventions are
to be devised and used early in the course of the disease. There is therefore a
pressing need for more sensitive and speciﬁc diagnostic tests with which we can
detect Alzheimer’s disease in the preclinical stage. The tau proteins and beta-
amyloid proteins start to accumulate 20 years before the symptoms begin to
manifest. Detecting them in the preclinical stage would be a potential
breakthrough in the management of Alzheimer’s disease. A high degree of
clinical suspicion is needed to correlate problems in cognition with the changes in
the eye, particularly the retina, pupil and ocular movements, so that the disease
can be detected early and managed in the prodromal phase. In this systematic
review, we ask the question whether the retina can be used to make a speciﬁc and
early diagnosis of Alzheimer’s disease.
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Introduction
About 46.8 million people in the world
are living with dementia in the year
2015. This number is predicted to
double every 20 years reaching 131.5
million in 2050. Alzheimer’s disease is
the most common cause of senile
dementia worldwide and accounts for
60–80% of all the cases of dementia
(Prince et al. 2015). Alzheimer’s disease
is an age-related neurodegenerative
disorder, characterized by cortical and
hippocampal atrophy. The clinical
symptoms are loss of short-term mem-
ory, impaired judgement and learning,
poor visuospatial perception and
reduced executive functions progress-
ing to a stage when the patient may not
recall previously well-remembered
information (Hardy 2006). The initial
symptoms are mistaken for ageing or
stress (Waldemar et al. 2007). The
disease progresses through three stages
– mild, moderate and severe. The early
stage is marked by episodes of forget-
fulness and confusion in unfamiliar
situations. In the middle stage, there
is difficulty in remembering recently
learned information, deep confusion in
some situations and problems with
sleep. In the late stage, there is poor
ability to think, difficulty in speaking,
and the patient becomes dependent on
the caregivers, which poses a serious
social, economic and psychological
problem to the society.
The cause for most Alzheimer’s cases
is still not known. Only in 1–5% of
cases, genetic diﬀerences have been
identiﬁed (Reitz & Mayeux 2014). The
basic pathology is intracellular hyper-
phosphorylated tau protein in the form
of tangles and deposits of beta-amyloid
protein. Beta-amyloid protein is also
the main constituent of senile plaques
(Ferreira et al. 2007; Chafekar et al.
2008; Sakano & Zako 2010)4 . There is
amyloid deposition in the cortex and
hippocampus. These pathological
changes lead to dysfunction of synapses
and loss of neurons. The uncoupling of
tau proteins from the microtubules
results in microtubule disassembly.
Most of the drug treatments are
based on the cholinergic hypothesis,
which states that the cause of AD is
reduced synthesis of the neurotrans-
mitter acetylcholine (Francis et al.
1999). The medications currently used
to treat the cognitive problems of AD
are tacrine, rivastigmine, galantamine,
donepezil (which are acetyl-
cholinesterase inhibitors) and meman-
tine, which is a NMDA receptor
antagonist. There is evidence for the
use of these drugs in mild-to-moderate
Alzheimer’s disease (Birks 2006)5 and
some evidence for their use in the
advanced stage. The drug used for the
treatment of advanced AD dementia is
donepezil, but the beneﬁt from its use is
small (Birks & Harvey 2006). Overall,
these drugs do not help to stop or
reverse the progression of the disease.
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The recognition of the pathophysio-
logical mechanisms in AD has led to
identiﬁcation of targets for the devel-
opment of speciﬁc drugs. More than
200 compounds are undergoing phase 2
and phase 3 trials (Hampel 2012).
These drugs have been divided into
anti-amyloid agents and drugs that
target other pathological pathways.
Immunotherapeutic agents like
bapineuzumab, solanezumab, gan-
tenerumab, ponezumab and crenezu-
mab have a high affinity to antigenic
determinant epitopes of beta-amyloid6 .
They are then recognized by the B and
T cells and cleared from the brain
(Burstein et al. 2013). A vaccine
CAD106 undergoing phase 1 trial
may be able to reduce beta-amyloid
accumulation by binding to the amy-
loid aggregates and blocking cellular
toxicity. Other drugs directed against
tau protein are methylene-blue (Rem-
ber), NAP (AL-108) and lithium. The
former two favour the stabilization of
microtubules, while lithium salts pre-
vent tau hyperphosphorylation (Taka-
shima et al. 2013)7 . A phase III clinical
trial ‘Anti-Amyloid Treatment in
Asymptomatic Alzheimer’s Disease’ is
recruiting cognitively normal adults
whose brain scans show evidence of
amyloid build-up, which places them at
risk for memory loss and cognitive
decline, to determine whether an anti-
amyloid investigational drug, solane-
zumab (a monoclonal antibody), can
slow memory and cognitive decline and
aﬀect the build of amyloid plaques
which is shown by brain imaging and
other biomarkers in these people. Fur-
ther trials are needed to target disease
modiﬁcation in patients with very mild
clinical symptoms (Dubois et al. 2010).
The ocular changes in Alzheimer’s
disease include decreased vision,
abnormal pupillary reaction, decreased
contrast sensitivity, visual ﬁeld
changes, loss of retinal ganglion cells
and retinal nerve ﬁbre layer, peripapil-
lary atrophy, increased cup–disc ratio,
retinal thinning, tortuosity of blood
vessels and deposition of beta-amyloid
in the retina. The changes in the brain
are at molecular level and disease
progression is difficult to detect, requir-
ing methods that are expensive and
invasive. When the disease has pro-
gressed considerably, with signiﬁcant
damage to the brain, a diagnosis of
‘probable AD’ is made (McKhann
et al. 1984). Changes in the brain are
a sign of late stage AD and the
symptoms of cognitive decline have
already set in. Recent studies suggest
that the changes in the retina occur
early, thereby suggesting the possibility
for earlier diagnosis and subsequent
treatment of AD (Koronyo et al.
2011). The development of sensitive
biomarkers to detect these changes in a
timely fashion is therefore needed.
Advanced modern techniques have
made it possible to visualize the
changes in the retina at a very ﬁne
level. By detecting neurodegenerative
changes in the eye, the hope is that we
may be able to diagnose, manage and
plot the progression of Alzheimer’s
disease at a very early stage (Heaton
et al. 2015). The fact that the retina
develops from the diencephalic invagi-
nation of the pluripotent cells allows
the retina to share many morphological
similarities with the brain (Ran et al.
2009) and the eye is easily accessible
because it is not enclosed by the skull
or spine. Therefore, the retina can be
used to study CNS disease and its
pathology.
Biomarkers are a subclass of
endogenously occurring indicators,
which signify the pathological state
(Rachakonda et al. 2004)8 . An ideal
biomarker is speciﬁc, sensitive, non-
invasive, inexpensive, reproducible,
suitable for large-scale population
screening and readily available. This
challenging set of criteria makes the use
of current biomarkers limited (Cedazo
& Winblad 2010; Humpel 2011). There
are various changes in the retina in
Alzheimer’s disease, which can be
detected using non-invasive retinal
imaging techniques (Fig. 1). They are
described subsequently in this review
with their advantages and disadvan-
tages. The National Institute of Aging
(NIA) has set certain guidelines to
make an accurate diagnosis of AD
focusing on the following stages of
Alzheimer’s disease:
(1) Dementia
(2) Mild cognitive
(3) Preclinical
(4) Changes observed in an autopsy
According to these guidelines, the
following categories of biomarkers
have been deﬁned (Cliﬀord et al. 2011):
(1) Category one describes the bio-
marker of amyloid accumulation and
tau protein, which can be detected in
brain by amyloid imaging using PET
scan, and levels of tau protein in the
CSF (Engler et al. 2006; Schoonen-
boom et al. 2008; Mulder et al. 2010;
Nordberg 2010).
(2) The second category describes the
marker of neuronal degeneration and
injury-tau protein in the cortex mea-
sured by C.S.F. analysis. The brain
volume changes are measured by
M.R.I (Dierks et al. 2000; Sunderland
et al. 2003; Maheswaran et al. 2009;
Luckhaus et al. 2010)9 .
(3) The third category describes
changes at physiological level cell
Fig. 1. Retinal changes in AD and methods of detecting them using non-invasive retinal imaging
techniques.
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death, synaptic damage, oxidative
stress and inﬂammation. How useful
these measures are is still being deter-
mined (Kiddle et al. 2014). The fact
that some of these markers are invasive
led the NIA to conclude that extensive
work was needed before these guideli-
nes were adopted for clinical purposes.
Methods10
Systematic review
We searched the MeSH database for all
human and animal reviews, clinical and
comparative studies, published in any
language in the past 5 years from
March 2011. Initial search terms were
‘retina’ and ‘Alzheimer Disease/diag-
nosis’. Additional publications were
identiﬁed from references in the pre-
liminary literature and subsequent
updates. Devices selected for analysis
do not constitute a comprehensive list
of worldwide research but were chosen
for signiﬁcant progress addressing the
question if the retina can be used to
diagnose and plot the progression of
Alzheimer’s disease, comparing the
strength of evidence in humans with
experimental animals and establishing
whether they are speciﬁc and sensitive.
Data extraction
We initially screened all studies identi-
ﬁed in the systematic search of the
online databases by abstract and title in
the last 5 years. Irrelevant or duplicate
studies were removed, and the remain-
ing articles were assessed for eligibility
by full-text review. Data extracted
from these studies included: title,
authors, publication year, aim of study,
study type, disease focus, results and
suggestions made by authors.
Results
Using the MeSH database, 102 papers
were identiﬁed, of which 51 were
included as they were in the last
5 years. These 51 were screened by
abstract and title only. Twelve seemed
ineligible at this stage, which included
two reviews. These two reviews were
excluded because they were not speciﬁc
to the question addressed in this sys-
tematic review. Three were excluded, as
they were an abstract-only conference
presentation with no speciﬁc content.
The total number of papers that were
included was 36. Of 36 papers included,
seven were review articles.
Results of review of systematic evidence
Optical coherence tomography. The
changes in the retina in Alzheimer’s
disease generally comprise thinning of
the nerve ﬁbre layer and loss of the
retinal ganglion cells, which can be
detected utilizing optical coherence
tomography (OCT). The current reso-
lution of commercial OCT is 15 lm.
The advantages are that it is fast, non-
invasive, readily available and inexpen-
sive (Cost et al. 2006). Spectralis OCT
resolves the retina to 5 lm or even less,
acquires images quickly and distin-
guishes the retinal layers. Faster acqui-
sition improves the reliability of the
technique. The disadvantage of OCT is
that it cannot be used to distinguish
between the diﬀerent types of dementia
because of low sensitivity. Moreno–
Ramos have characterized retinal
changes across diﬀerent types of
dementia including dementia with
AD, dementia with Lewy bodies and
Parkinson’s-associated dementia (Mor-
eno Romos et al. 2013). No statistically
signiﬁcant diﬀerences in RFNL thick-
ness between diﬀerent types of demen-
tia have been observed.
Studies have shown that the cogni-
tive impairment in Alzheimer’s disease
as determined by mini-mental status
examination has a positive correlation
with the reduction in macular volume
(Parnell et al. 2012). In the patients
with mild cognitive impairment, which
is an early stage of Alzheimer’s disease,
signiﬁcant reduction in the retinal
nerve ﬁbre layer has been shown in
studies (Iseri et al. 2006). It has been
documented in studies, that the ﬁrst
aﬀected area is the macular area in
Alzheimer’s disease, which is followed
by a signiﬁcant decline in the peripap-
illary thickness of the retinal nerve ﬁbre
layer. The most sensitive area is the
superior inner macula (Garcia-Martin
et al. 2014). In patients with Alzhei-
mer’s disease, there is a typical inferior
ﬁeld loss, which corresponds to the
superior loss of the retinal nerve ﬁbre
layer (Trick et al. 1995). The most
sensitive protocol for detecting this
subclinical atrophy is the Nsite Axonal
Analytics application of Spectralis
OCT.
In a meta-analysis consisting of 11
studies with 380 patients with Alzhei-
mer’s disease, 68 of who had mild
cognitive impairment, and 293 healthy
controls, retinal nerve ﬁbre layer thick-
ness was measured by means of OCT
(Li et al. 2009). The mean retinal
thickness was reduced in mild cognitive
impairment (p value 0.031) and in AD
(p value 0.0001). The study found
signiﬁcant decrease in thickness in each
quadrant, reﬂecting the fact that the
degenerative process aﬀects the entire
retina (Li et al. 2009). This study sup-
ported the fact that analysis of the
retinal nerve ﬁbre layer with OCT
could be used to monitor the progres-
sion in Alzheimer’s disease patients and
also the eﬀectiveness of future treat-
ment in patients with AD.
With the development of spectral
domain OCT and shift towards the
longer wavelengths of light, choroidal
thickness and area can be measured
(Margolis & Spaide 2009; Ikuno et al.
2010;11 Manjunath et al. 2010). Ghar-
biya et al. (2014) have reported signif-
icant thinning of the choroid. The main
disadvantage is that inability of chor-
oidal OCT to distinguish AD from
other diseases like glaucoma (Alonso
Canerio et al. 2013; Park et al. 2014;
Zhang et al. 2014). Whether the
patients with mild cognitive impair-
ment and retinal thinning have a higher
incidence of conversion to AD is not
still determined and studies are needed
to address this question (Winblad et al.
2004). Spectralis has a good sensitivity
of 94.3% and speciﬁcity 95%. In a
study by Martin et al. (2016)12 , 150
patients with AD and 75 age-matched
healthy controls were analysed using
macular scans and association between
retinal layer thickness, disease duration
and AD severity was evaluated.
Patients with AD had reduced thick-
ness in the retinal nerve ﬁbre layer,
ganglion cell, inner plexiform and outer
nuclear layers (p < 0.05). The inner
layers of the retina were more aﬀected
in patients with long-duration disease
and the ganglion cell and retinal nerve
ﬁbre layer thickness were inversely
corelated with AD duration and sever-
ity, indicating that ganglion cell reduc-
tion was associated with increased
axonal damage and may predict greater
disease severity.
Bambo et al. (2014)13 found out sig-
niﬁcant thinning in the superior and
inferior retinal nerve ﬁbre layer in
Cirrus OCT and signiﬁcant thinning
in the inferior and infero-temporal
retinal nerve ﬁbre layer in Spectralis
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OCT. They also found that colour
vision assessment is better corelated
with disease severity (Tas et al. 2015).
Risacher et al. (2013)14 found that dis-
turbances in contrast sensitivity are
present even in the early stages of
AD. They also demonstrated a corre-
lation between contrast sensitivity and
the mini-mental status score. They also
found a signiﬁcantly positive correla-
tion between colour confusion index
(to assess the severity of dyschro-
matopsia) and Lanthony 15D test with
disease duration (0.973, p = 0.027).
Thus, colour vision impairment could
be a good biomarker for diagnosis and
follow-up of AD (Bamboo et al. 201515 ).
Colour vision assessment is better cor-
related than RNFL thickness with
disease activity in other neurodegener-
ative diseases, such as multiple sclerosis
(Gundogan et al. 2007).
The results of 10 studies, showing
the comparative analysis with statisti-
cal signiﬁcance of the retinal ﬁndings,
choroidal ﬁndings and changes in the
optic nerve volume as measured by
OCT in patients with AD, patients with
mild cognitive impairment and controls
are summarized in Table 1.
Doppler and retinal photography to detect
changes in retinal vasculature. In amy-
loid angiopathy, beta-amyloid deposits
in the walls of arteries and arterioles
result in a narrowed lumina and even-
tually occlusion (Ellis et al. 1996; Vin-
ters et al. 1996; Jellinger 2002; Tian
et al. 2006). The retinal vascular
changes in AD include narrow veins,
decreased retinal blood ﬂow in veins,
reduced complexity of the branching
pattern, reduced optimality of the
branching geometry and less tortuous
venules (Heaton et al. 2015).
The ﬁrst study that reported the
retinal vascular changes in AD was a
small participant study by Berisha
et al. (2007). Further studies carried
out by Frost et al. and Chang et al.
suggest that retinal venular narrowing
is associated with AD and the reason
for this is the increased collagen depo-
sition in the cerebral veins (Cheung
et al. 201423 ). With the help of advances
in retinal imaging, measurements of the
minute abnormalities in the retinal
microcircuitry enable accurate results
(Witt et al. 2006). In a study of 52
subjects (10 AD, 21 mild cognitive
impairment and 21 normal controls),
blood column diameter, blood speed
and blood ﬂow were measured in a
major temporal retinal vein using reti-
nal laser Doppler ﬂowmetry. This
study reported that blood ﬂow abnor-
malities might precede the neurodegen-
erative changes in the brain in
Alzheimer’s disease (Feke et al. 2015;
Fig. 2).
A comparative analysis of 11 studies
comparing the ocular and haemody-
namic parameters, with statistical sig-
niﬁcance in patients with AD and
healthy controls, have been described
in Table 2.
The Australian Imaging, Biomarkers
and Lifestyle Flagship study of Aging
is the ﬁrst study that correlated the
changes in the retinal blood vessels to
the plaque burden in the brain. Venular
branching asymmetry factor and arte-
riolar length to diameter ratio are
higher in healthy individuals with high
plaque burden (Frost et al. 2013).
Retinal photography using 500 canon
CR Dgi after dilating the pupil with
1% tropicamide was used in the
patients with the help of a semi-
automated computer-assisted program
– Singapore1 Vessel Assessment Soft-
ware. This software uses the optic disc,
placing a grid with the centre of the
optic disc, identifying the vessel type
and calculating the retinal vessel
parameters. A study using this software
found out that the patients having the
lower value of venular fraction or
lower arterial tortuosity were more
likely to develop AD after the adjust-
ment of age, smoking, hypertension,
diabetes, cardiovascular, cerebrovascu-
lar and drug use. However, this study
could not demonstrate association
between vascular parameters and
mini-mental status examination.
In a study by Carol et al. (2014)25 , 136
dementia patients with AD and 290
age-matched controls were studied,
retinal photographs were taken, and
retinal microvascular parameters were
measured. They included 136 dementia
patients with AD and 290 controls.
Persons with narrower venular calibre,
decreased arteriolar and venular fractal
dimension, increased arteriolar and
venular tortuosity were more likely to
have Alzheimer’s disease. These
changes in the retinal microvasculature
may indicate similar pathophysiologi-
cal changes in the brains of patients of
AD.
Atherosclerosis Risk in Communi-
ties (Knopman et al. 2016) developed
software in which the vessel calibre
was measured within a zone that was
0.5–1 disc diameter away from the
optic disc margin. Central retinal
artery equivalent, vein equivalent and
arteriovenous ratio are the parameters
which measure changes in vascular
calibre. Changes in the retinal vascular
width and branching angle occur early
in the course of AD during the point
when there is asymptomatic plaque
deposition. The following haemody-
namic parameters and retinal zones
were deﬁned:
1 Fractal dimension: Property of self-
similarity in 2-dimensional spaces.
2 Tortuosity: Degree of straightness or
waviness of a vessel.
3 Bifurcation angle: First angle sub-
tended between the two daughter ves-
sels at each bifurcation.
4 Branching coefficient: Branching
vessel width/trunk vessel width.
Table 1. The results of 10 studies, showing the comparative analysis with statistical signiﬁcance of
the retinal ﬁndings, choroidal ﬁndings and changes in the optic nerve volume as measured by OCT
in patients with AD, patients with mild cognitive impairment and controls16 .
AD MCI Control P value Author
1. Average
RFNL
thickness
(in lm)
84.7  10.6 85.8  10 94.3  11 0.05 Kesler et al. (2011)17
64.75  15.18 86.03  7.26 103.57  8.94 0.001 Ascaso et al. (2014)18
91.83  6.23 97.49  6.09 0.001 Bayhan et al. (2015)19
97.4 99.2 0.106 Polo et al. (2015)20
95 89 0.001 Bamboo et al.
(2015)
89.4 100.9 0.002 Bamboo et al.
(2015)
65  6.5 72  3.8 0.001 Kerbas et al. (2012)21
2. Choroidal
Thinning
221.48  40.33 251.86  48.03 0.01 Bayhan et al. (2015)
200  70.7 266  93.5 0.001 Gharbiya et al.
(2014)
3. Optic nerve
Volume
3.68  0.62 4.19  0.60 0.001 Kusbeci et al. (2012)22
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Frost et al. (2013) have reported a
sensitivity of 81.2% and speciﬁcity of
75.7% using 13 retinal vascular param-
eters in patients with AD (Frost et al.
2013). A large number of population-
based studies have shown the associa-
tion of retinal changes with cognitive
impairment. Retinal arteriolar narrow-
ing, venular widening and suboptimal
retinal bifurcation are associated with
impaired cognitive performance (Parisi
2003; Witt et al. 2006; Reitz et al. 2011;
Frost et al. 2013; Al Fiadh et al. 2014).
Sparse retinal microvascular network is
also associated with AD. The strength
of association for these parameters is
weak (Williams et al. 2015)26 . Future
work will be needed to evaluate
whether the changes alone can serve
as an independent biomarker in AD.
Image analysis software. The fact that
there is homology between the cerebral
and retinal circulations helps us to use
the retinal microvascular changes as a
biomarker in dementia through
non-invasive and easily accessible
retinal imaging techniques. Cheung
et al. (2014) studied retinal pho-
tographs in patients with AD. They
used a laser Doppler device to assess
retinal blood ﬂow in patients with AD.
They found out thinning in the retinal
microvasculature of patients with AD
as compared to the controls. Retinal
vascular imaging can give a clue to the
vascular mechanisms contributing to
the development of AD. The Laguna
ONhE software, which is colorimetric
analysis software, can be used to assess
the colour of the optic disc. The optic
disc in patients with AD is pale due to
perfusion alteration and axonal loss in
the early stages. This can be used an
early biomarker in AD (Bambo et al.
2015). The mean haemoglobin percent-
age and haemoglobin content in the
outer ring, which corresponds to the
neuroretinal rim, is signiﬁcantly lower
in patients with AD. In glaucoma
patients, this program evaluating hae-
moglobin in the vertical intermediate
sectors and centre/periphery haemoglo-
bin has 89.1% sensitivity and 95.1%
speciﬁcity, which is similar to the other
tests.
Johnson et al. (2002)27 were the ﬁrst
to report beta-amyloid protein in the
subvesicular component of a drusen in
eyes with age-related macular degener-
ation. Further studies by Csincsik et al.
(2016) have found that in patients with
AD, there is signiﬁcantly higher preva-
lence of hard drusen in the peripheral
retina (p < 0.05) which increase signif-
icantly in the 2-year follow-up period
(p < 0.05) suggesting that imaging the
drusen could be used to plot the
progression of AD. Ultra wide-ﬁeld
and OCT images were acquired by
Optos 200TX and Optos OCT SLO.
Seventy-two healthy controls and 46
patients with AD (mini-mental score
examination <20) were analysed for
presence, absence and progression of
drusen at baseline and at 2-year follow-
up. The development of AD is associ-
ated with thinning of the nerve ﬁbre
layer and accumulation of drusens,
which reﬂect atrophy and plaque
deposits in the brain. Ultra wide-ﬁeld
angle imaging might become a useful
tool in monitoring the progression of
AD.
Heather Whitson et al. conducted a
study where 15 patients with mild
cognitive impairment (MCI)/prodro-
mal AD, 15 patients with moderate
AD, 17 cognitively normal adults were
enrolled. They underwent examination,
spectral domain optical coherence
tomography, wide-ﬁeld fundus, colour
and autoﬂuorescence photography and
stereo disc photography. Duke Optical
Coherence Tomography Retinal
Fig. 2.43 Retinal zones utilized for retinal vascular analysis: Zone A: The region from 0 to 0.5 disc
diameters away from the disc margin. Zone B: The region from 0.5 to 1.0 disc diameters away
from the disc margin. Zone C: The region from 0.5 to 2.0 disc diameters away from the disc
margin. D0 is the main branching trunk. D1 and D2 are the branches, and the branching angle is
the angle between the perpendicular and D1 and D2.
Table 2. A comparative analysis of 11 studies comparing the ocular and haemodynamic
parameters, with statistical signiﬁcance in patients with AD and healthy controls.
AD (Mean)
Control
(Mean) p Value Study
Visual acuity 74.3  3.3 74.3  5.8 0.97 Berisha et al. (2007)
Intra-ocular pressure 14.4  4.4 13.3  3.3 0.53 Berisha et al. (2007)
Superior quadrant
RNFL (in lm)
92.2  22.6 113  10.7 0.02 Berisha et al. (2007)
Central retinal
arterial equivalent
112.8 110.8 0.029 Berisha et al. (2007)
Central retinal
venous equivalent
159 158.9 0.951 Berisha et al. (2007)
Arterial tortuosity 0.876 0.921 0.03 Williams et al. (2015)24
Venous tortuosity 1.016 1.035 0.458 Williams et al. (2015)
Arteriolar branching angle 78.3 79.17 0.523 Williams et al. (2015)
Venular branching angle 80.38 79.86 0.599 Williams et al. (2015)
Retinal arteriolar
02 concentration
94.2  5.4% 90.5  3.1% 0.028 Cheung et al. (2014)
Retinal venular
02 concentration
51.9  6% 49.7  7% 0.02 Cheung et al. (2014)
L
O
W
R
E
S
O
L
U
T
IO
N
C
O
L
O
R
F
IG
5
Acta Ophthalmologica 2017
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
Analysis Program (DOCTRAP) soft-
ware was used to measure nerve ﬁbre
layer thickness. Retinal specialists
graded drusens and the proportion of
participants with evident drusen were
compared by chi-square test. After
one-year follow-up, they have reported
that peripheral drusen are visible in
66.7% of patients with AD as com-
pared to 35.7% patients with mild
cognitive impairment or 35.5% con-
trols patients (p value is 0.06), and this
ﬁnding was bilateral in 16 of 17 sub-
jects (Whitson et al. 2016).
A non-invasive retinal imaging
device has been developed by Cedars–
Sinai Medical Centre that can detect
changes that occur 15–20 years before
the clinical diagnosis. According to
Frost (Frost et al. 2013), in the initial
results in 40 patients, the test could
distinguish between AD and non-AD
patients with 100% sensitivity and 84%
speciﬁcity. In the data from 40 patients,
amyloid levels detected in the retina
were correlated with brain amyloid
levels as shown by PET imaging. An
average increase in 3.5% retinal amy-
loid during a 3.5-month period sug-
gested that the technique could be used
for monitoring the response to therapy
as well.
Retinal oximetry. Jong et al. (2011)
examined vascular patterns in dementia
and reported that wider retinal venules
are associated with an increased risk of
vascular dementia. The use of spec-
trophotometric retinal oximetry mea-
sures oxygen saturation in blood
vessels. Another study has conﬁrmed
that the retinal oxygen saturation in
retinal arterioles and venules is signif-
icantly elevated (Einarsdottir et al.
2015). Oxygen delivery is the product
of the blood ﬂow and the arteriovenous
diﬀerence in oxygen concentration. As
reported by Berisha et al. (2007) if the
blood ﬂow is reduced, there is a
decrease in oxygen delivery, which
explains the elevated oxygen saturation
in these patients. Retinal oximetry is a
non-invasive test with a potential to
detect not only ocular but systemic
vascular health. However, the reliable
evaluation and monitoring of retinal
architectural changes have been limited
by the subjective nature by which these
parameters are assessed.
Electroretinography. An early com-
plaint of patients with AD is visual
disturbance. Visual ﬁeld, colour
vision, contrast sensitivity and visual
perception are aﬀected in patients of
Alzheimer’s disease. Instead of record-
ing the electroencephalogram, the elec-
troretinogram can be used as an
alternative to detect pathology in the
early stages. There is a signiﬁcant delay
in N35, P50 and N95 components of
the pattern electroretinogram. Reduc-
tion in b-wave amplitude occurs and
can be explained due to the reduced
number of ganglion cells in the retina
of patients with AD. Visually evoked
potential shows changes in patients
with AD, which are detected when the
pathology is advanced. There is latency
of the ﬂash P2 component of the
cortical VEP. There is impairment of
synaptic organization in AD. This
occurs before the neuronal loss, and
therefore, it is a better indicator of the
cognitive decline (De Kosky & Scheﬀ
1990; Jindal 2015)28 . In patients with
AD, ERG had a speciﬁcity of 93% and
a sensitivity of 70% and the results
were similar to the ﬁgures published by
Coben et al. (1990). As the defects are
at many steps from the retinal ganglion
cells to the cortex, these tests could be
used as screening tools for early AD
detection (Dehabadi et al. 2014).
PET imaging. Detecting amyloid pla-
ques in the retina of patients is a
diagnostic tool, and it holds great
promise in the future. PET scan is a
nuclear medicine, functional imaging
technique used to measure metabolic
processes in the body. The PET scan
detects a pair of gamma rays emitted
indirectly by a tracer, which is intro-
duced in the body on a biological active
molecule. PET scan imaging uses (C-11
or F18) Pittsburgh compound-B (PiB;
Mulder et al. 2010), which is biologi-
cally active. With this technology, the
plaques can be detected at the same time
as when the symptoms arise and there-
fore the disease can be picked up and
managed early and efficiently (Schoo-
nenboom et al. 2008). When the disease
progresses and symptoms become man-
ifest, there is increase retention of Pitts-
burgh compound in the plaques and
therefore the progression can be moni-
tored as well (Sunderland et al. 2003).
The disadvantage of this promising
technique is that in one-third of the
patients with cognitive impairment not
due to AD also have retention of Pitts-
burgh compound-B PiB in the plaques.
This technique is also expensive and has
limited availability. Microglial activa-
tion has a mitochondrial marker, which
is expressed, in low levels in resting
microglial cells but when there is inﬂam-
mation cognitive, this marker increases,
and in the advanced stages of the
disease, speciﬁc radio ligands have been
used with positron emission tomogra-
phy (PET) imaging. AmyvidTM(ﬂorbe-
tapirF18),VizamylTM(ﬂutemetamol) and
NeuraceqTM (ﬂorbetaben F18) are
radioactive tracers which have been
recently approved by the U.S. Food
and Drug Administration for positron
emission tomography (PET) imaging of
the brain to estimate the beta-amyloid
plaque density. This technique carries
the risk of potentially toxicity and is also
invasive. Various positron emission
tomography approaches show a similar
sensitivity (range 80.0–100%) and speci-
ﬁcity (range 62.0–90%) as compared to
CSF ﬂuid tau sensitivity (range 73.3–
100%) and speciﬁcity (range 70.0–
92.4%; Gaugler et al. 2013).
Research by Synder et al. (2016)
described a non-invasive approach to
ﬁnd Alzheimer’s early PET and OCT
scans to observe microscopic details.
Sixty-three patients who were high risk
for Alzheimer’s disease based on
emerging symptoms and family history
were included. The researchers ﬁrst
conducted PET scans to establish the
extent of the participants’ beta-amyloid
accumulation. Then, they performed
OCT scans and compared the results.
They used a technique called blue laser
autoﬂuorescence in conjunction with
the OCT. The OCT scan cannot
directly detect beta-amyloid proteins,
but it revealed shadow-like inclusion
bodies that correlated well with the
level of beta-amyloid close to the retina
revealed by the PET scan. The surface
area of the inclusion bodies increased
as a function of cortical amyloid bur-
den with a greater increase in the inner
plexiform layer which is rich in cholin-
ergic activity.
If the OCT reveals evidence of beta-
amyloid, a PET scan could be per-
formed for a more detailed assess-
ment. This is the ﬁrst study to
demonstrate the results in a preclinical
AD population.
Curcumin. Yang et al. (2004)29 have
reported that curcumin, which is a
naturally occurring phytochemical
extract from the rhizome of Curcuma
longa L. (Reinke & Gestwicki 2007)
binds to the beta-plated structure of
amyloid can be used as a staining agent
for the amyloid plaques and it also
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decreases their density (Ho et al. 2012).
When injected i.v or administered
orally, it has been seen in mouse
models that it crosses the blood brain
barrier and stains the amyloid plaques
in the brain (Yang et al. 2005; Garcia
Alloza et al. 2007) and retina (Dhillon
et al. 2008)30 . This technique is very
speciﬁc and has been used in live
transgenic mice with high resolution
and speciﬁcity (Krantic & Torriglia
2014). A signiﬁcant advantage of cur-
cumin is that it is safe even at higher
doses (12 g per day) and even when it is
used over longer periods (Reinke &
Gestwicki 2007). The disadvantages are
limited bioavailability due to poor
absorption, rapid metabolism and
quick elimination from the body
(Aggarwal et al. 2003; Ringman et al.
2005; Begum et al. 2008)31 . Methods
have been developed recently to
increase the stability and increase the
availability in vivo (Anand et al. 2007).
Curcumin derivatives can be used as a
marker in PET scanning as suggested
by Ryu et al. (2006). Researchers at the
Commonwealth Scientiﬁc and Indus-
trial Research Organization in Aus-
tralia used curcumin ﬂuorescence
imaging to highlight beta-amyloid in
the retina and correlated them with the
PET ﬁndings in the brain. The ability
of curcumin to cross the blood brain
barrier, bind to the beta-amyloid pla-
ques and dissolve them with less toxi-
city makes it a promising tool to
diagnose and treat AD. According to
the researchers, the retinal amyloid test
was able to diﬀerentiate between Alz-
heimer’s disease and non-Alzheimer’s
disease with 100% sensitivity and
80.6% speciﬁcity. The retinal amyloid
test is a potential initial screen that can
complement the currently used tests
and could potentially be delivered as
part of regular eye checks.
Fluorescent ligand eye scanning system
(FLES). To distinguish between prob-
able patients with AD and healthy
individuals, a new technique called the
Fluorescent Ligand Eye Scanning
(FLES) System is being developed.
This technique has a sensitivity of
85% and a speciﬁcity of 95%,
(p < 0.001). It uses a laser eye scanning
device and a ﬂuorescent marker to
mark the plaques (Sadowsky et al.
2014). Currently, this technique is in
the phase 2 of clinical trials. A high
concordance between amyloid PET
and FLES has been found. Pilot studies
have suggested the safety, feasibility
and utility of distinguishing patients
with AD from healthy controls. Fur-
ther studies on a large-scale population
with multiple comparisons and autopsy
validation are needed to conﬁrm the
prognostic utility of the test (Sadowsky
et al. 2014). The researchers found that
the patients with Alzheimer’s disease
and healthy volunteers were diﬀerenti-
ated with a sensitivity of 85% and
speciﬁcity of 95%. In addition, FLES
showed a strong correlation with amy-
loid PET imaging. This appears to give
us a way to predict Alzheimer’s
changes in the brain before they occur,
and it may give us a simple and cost-
eﬀective way to gauge disease progres-
sion and treatment beneﬁt.
Fluorescence lifetime imaging ophthal-
moscopy. Another new technique called
ﬂuorescence lifetime imaging ophthal-
moscopy (FLIO) has been developed
which demonstrates changes in the
retina of patients of AD. It uses a
scanning laser ophthalmoscope cou-
pled to an excitation pulse laser BLD
440 and detects ﬂuorescence lifetime
(Jentsch et al. 2015). It measures ﬂuo-
rescence lifetime by measuring time
correlated single photon counting in
two spectral channels. In patients with
AD, the ﬂuorescent component of the
second channel correlates with the
mini-mental status examination and
tau protein concentration in the
C.S.F. In a study by Jentsch et al. 16
patients with AD, the FLIO parame-
ters of the second ﬂuorescent compo-
nent signiﬁcantly corelated with mini-
mental score examination as well as tau
protein concentration in the CSF. The
limitation of the study was low number
of subjects, but the strong correlation
with Alzheimer’s disease was interest-
ing and a study with large number of
subjects should be planned in the
future to conﬁrm the initial results.
Diﬀuse tensor imaging is another
technique, which can demonstrate that
the damage in patients with AD
extends down the visual pathway. In
patients with AD, diﬀuse tensor imag-
ing shows increase in total diﬀusivity,
radial diﬀusivity and decreased frac-
tional isotropy in the optic nerves
(Nishioka et al. 2015). This technique
is sensitive and speciﬁc and has been
used to demonstrate beta-amyloid pla-
ques ex vivo in mouse and human
retina and in vitro screening of chem-
ical compounds for amyloidogenesis.
The sensitivity and speciﬁcity of
ﬂuorescence in the detection of amy-
loid-b in human retinas of patients with
Alzheimer’s disease (AD) have been
studied. It is an accepted marker of
disease, used for diagnosis post-mor-
tem, so its presence in the retina
presents an opportunity for a non-
invasive diagnostic. Ex vivo retinas
were stained with thioﬂavin S and ﬂat
mounted from eyes of those with a
diagnosis of AD (n = 19) and those
with no history of AD (n = 18) and
excluded those with a diagnosis of
glaucoma. Retinas were examined
using ﬂuorescence in both transmission
and confocal scanning microscopy for
amyloid-b deposits. In diseased retinas
(deﬁned by an AD diagnosis and pos-
itive ﬂuorescence), the number of ﬂuo-
rescing deposits also had polarization
contrast. Thioﬂavin S staining in the
retina shows 84.2% sensitivity and
72.2% speciﬁcity in detecting AD.
The use of crossed circular polarization
showed a high speciﬁcity to amyloid-b
deposits but produced some false neg-
atives. This method shows promise for
the imaging of amyloid-b in the retina
of the living eye as a marker of AD
(Emptage et al. 2014).
Studies in animal models
Some promising techniques for the
future have been used and tested in
animal models. Multiphoton micro-
scopy is a technique using ﬂuorescent
dyes AO1-987 and CRANAD-2, which
emit light in the near-infrared spec-
trum. It has been used in animal
models. The advantage of this tech-
nique is that it is speciﬁc and can be
used in PET scan by radiolabelling
(Ran et al. 2009). The disadvantage is
that the procedure is highly invasive
requiring a cranial window.
Direct visualization of the beta-amy-
loid plaque in the retina could diagnose
AD preclinically. The neuropathologi-
cal hallmarks have been conﬁrmed in
the retina using transgenic mouse mod-
els of AD. Whole mount retinae of
transgenic mice have demonstrated
beta-amyloid structures in the retina
(Ning et al. 2008; Liu et al. 2009; Peterz
et al. 2009)32 .Histological examinationof
the retinal cross sections reveals elevated
amyloid plaques in the RGCs, RNFL
and superﬁcial retinal layers (Ning et al.
2008; Peterz et al. 2009)33 .
Using retinal imaging techniques,
plaque formation and clearance
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following immunotherapy, in which
altered myelin antigen is loaded on
dendritic cells, can be used in vivo and
can be used to demonstrate the pro-
gress of the disease. The eﬀects of the
therapy can be visualized by plaque
reduction, and this can be very promis-
ing for therapy assessment in humans.
Future studies are needed in this direc-
tion so that the disease progression can
be monitored in humans (Yosef et al.
2012). Altered excitability in the neu-
rons has been reported in the hip-
pocampus in a transgenic mice model
of Alzheimer disease. Future studies
detecting altered neuronal excitability
in the retina are needed to conﬁrm its
use as an early diagnostic marker
(Krantic & Torriglia 2014). Schon
et al. observed the progression of tau
protein pathology in vivo, using laser-
scanning ophthalmoscope. They could
also demonstrate hyperphosphorylated
tau protein in the human retina. They
suggested the use of ﬂuorescent probes
targeting the tau proteins as a biomar-
ker with great potential in the future.
Combining clinical and retinal imaging
biomarkers
Pupillometry is a sensitive technique
for the detection of early cholinergic
deﬁcits. It has been proposed that
pupillometry can be used as a diagnos-
tic tool in early stages of AD (Lim
et al. 2013). Reductions in pupillary
responses have been reported, but the
eﬀect is highly variable and it is difficult
to distinguish between patients with
AD and patients with Parkinsonism or
vascular dementia. Ability to ﬁxate,
saccades and pursuit movements are
aﬀected in patients with AD (Sadun
et al. 1987; Fletcher & Sharpe 1988;
Zaccara et al. 1992). These when com-
bined with a high degree of clinical
suspicion and retinal ﬁndings could be
very sensitive in the diagnosis of
Alzheimer’s disease.
Conclusion
As there is little evidence for the use of
currently available drugs in AD, there
is an ongoing and increasing need to
identify more AD-speciﬁc and sensitive
biomarkers in the retina, to detect the
disease in the preclinical stage allowing
neuroprotective interventions to slow
the progression of the disease.
Whether the retina can be used to
make a speciﬁc diagnosis of
Alzheimer’s disease and monitor pro-
gression is still open to question.
Retinal examination combined with
other ocular tests is a highly promis-
ing clinical biomarker for AD. As the
earliest complains in AD are visual
disturbances, visual function tests
especially colour vision can facilitate
the detection of AD. The decline in
retinal structure and function as doc-
umented by OCT and ERG suggests
the potential of using retinal exami-
nations, which are easy to perform
with other ocular tests. With improve-
ments in retinal imaging techniques
like Doppler, FLIO and FLES, which
are non-invasive and inexpensive, the
early diagnosis of AD is possible with
a detailed and early assessment of the
degenerative changes in the retinal
neurons and axons. They also enable
to detect the build-up of beta-amyloid
in the eye, early in the disease
progression.
Recent advances like dynamic vessel
analysis, retinal oximetry (Harazny
et al. 2011) and adaptive optic retinal
imaging (Moreno Romos et al. 2013),
provide a detailed analysis of the retina
including the retinal oxygen concentra-
tion, blood ﬂow, foveal capillary net-
work and choroidal vasculature
enabling retinal vasculature screening
to be used as a method for population
screening of AD (Moreno Romos et al.
2013). The retinal amyloid test is a
potential screening test that can com-
plement the currently used tests and
could potentially be delivered as part of
regular eye checks. Curcumin and
peripheral drusens are very promising
techniques to monitor the progression
of the disease.
A greater familiarization with these
techniques is required. The awareness
of the available imaging and analysis
methods could improve the ability to
understand the clinical relevance of the
retinal vascular changes that can be
used as very useful clinical biomarkers.
The deﬁnitive diagnosis currently
requires a combination of many
biomarkers with a high degree of clin-
ical suspicion to correlate problems in
cognition with the changes in the eye,
particularly the retina, pupil and ocular
movements, so that the disease can be
detected early and managed in the
prodromal phase. Careful characteri-
zation of cognitive changes and exclu-
sion of normal tension glaucoma is
critical.
More future work focusing on the
diagnostic, prognostic and therapeutic
value of using the retina, as a biomar-
ker to detect and monitor progress in
Alzheimer’s disease, will still be needed.
With the increasing evidence suggesting
the use of retina as a non-invasive
biomarker, it is very likely that one day
the retinal biomarkers will be used as
an early method of detecting groups at
increased risk of developing Alzhei-
mer’s disease.
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